Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 15;6:e2200197. doi: 10.1200/PO.22.00197

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License http://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

FIG 2. — Therapeutic response and 5-year outcomes by BluePrint. (A) The pCR rate of all 295 cHER2 patients (^adark gray bar) compared with pCR rates when stratified by BluePrint. The pCR rates of each BluePrint molecular subtype are shown (blue, cHER2/gLuminal; red, cHER2/gHER2; teal, cHER2/gBasal) with the remaining proportion of immunohistochemistry-/fluorescence in situ hybridization–defined HER2+ patients shown for each comparison in light gray bars: ^bcHER2/gHER2 and cHER2/gBasal, ^ccHER2/gLuminal and cHER2/gBasal, and ^dcHER2/gLuminal and cHER2/gHER2. Significance was evaluated using a two-tailed proportional z-test. Five-year probabilities of (B) DMFS and (C) OS for each BluePrint subgroup were assessed by the log-rank test. cHER2, clinically defined HER2+; DMFS, distant metastasis-free survival; gBasal, genomically defined Basal-Type; gHER2, genomically defined HER2-Type; gLuminal, genomically defined Luminal-Type; OS, overall survival; pCR, pathologic complete response.